SG Americas Securities LLC Makes New $72,000 Investment in Organogenesis Holdings Inc. (NASDAQ:ORGO)

SG Americas Securities LLC acquired a new position in Organogenesis Holdings Inc. (NASDAQ:ORGOFree Report) during the third quarter, according to the company in its most recent filing with the SEC. The fund acquired 25,086 shares of the company’s stock, valued at approximately $72,000.

A number of other institutional investors have also recently added to or reduced their stakes in ORGO. Pallas Capital Advisors LLC purchased a new position in Organogenesis in the second quarter valued at about $38,000. Delap Wealth Advisory LLC acquired a new stake in shares of Organogenesis during the second quarter worth approximately $40,000. Allspring Global Investments Holdings LLC grew its position in shares of Organogenesis by 4,989.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after buying an additional 15,369 shares in the last quarter. Mackenzie Financial Corp grew its position in shares of Organogenesis by 46.1% during the second quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock worth $68,000 after buying an additional 7,678 shares in the last quarter. Finally, CWM LLC grew its position in shares of Organogenesis by 301.8% during the second quarter. CWM LLC now owns 25,617 shares of the company’s stock worth $72,000 after buying an additional 19,242 shares in the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Stock Performance

ORGO opened at $2.95 on Tuesday. The company has a 50-day moving average of $2.87 and a 200-day moving average of $2.77. Organogenesis Holdings Inc. has a 1-year low of $1.96 and a 1-year high of $4.70. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.73 and a quick ratio of 2.42.

Organogenesis (NASDAQ:ORGOGet Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.11). Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. The firm had revenue of $130.23 million for the quarter, compared to analyst estimates of $122.48 million. As a group, analysts forecast that Organogenesis Holdings Inc. will post -0.17 EPS for the current year.

About Organogenesis

(Free Report)

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

Further Reading

Institutional Ownership by Quarter for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.